A meta-analysis published in the European Journal of Obstetrics, Gynecology, and Reproductive Biology reports that GLP-1 receptor agonist therapy was associated with higher odds of natural pregnancy in women with polycystic ovary syndrome compared with metformin alone. Overall pregnancy rates, however, did not differ significantly.
GLP-1 receptor agonists are the drug class behind semaglutide and its relatives, used for obesity and type 2 diabetes. The authors note they improve insulin resistance and promote weight loss in women with PCOS, a condition in which infertility is closely tied to metabolic dysfunction, but say their direct effect on reproductive outcomes has remained uncertain.
Key results
The review pooled four reports from three randomized trials covering 252 participants, drawn from PubMed, Scopus, and Web of Science searched through February 2026. Trials compared GLP-1RA therapy, alone or combined with metformin, against metformin monotherapy.
For overall pregnancy, the odds ratio was 1.41 with a 95% confidence interval of 0.81 to 2.45, which crosses one and so is not statistically significant. Natural pregnancy was the outlier: an odds ratio of 3.10, 95% CI 1.74 to 5.49, with trial sequential analysis supporting the finding.
The IVF gap
IVF pregnancy showed essentially nothing, an odds ratio of 1.01 with a confidence interval running from 0.36 to 2.85. The authors state plainly that current evidence is insufficient to draw conclusions about IVF outcomes.
That is a useful piece of honesty in a field where GLP-1 drugs are increasingly discussed around fertility clinics. A null result this imprecise is not evidence of no effect, it is evidence that nobody has run the trial yet.
Limitations
Three trials and 252 participants is a small base for any conclusion, and the authors rated certainty of evidence using GRADE as moderate for natural pregnancy and low for every other outcome. Trial sequential analysis found the overall pregnancy analysis still underpowered.
Live birth, the outcome that actually matters to patients, is not among the pooled results. The authors call for larger trials with standardized endpoints that include it.
Bottom line
The authors describe the natural conception signal as promising but preliminary, and say the available evidence remains limited. Whether that signal survives a properly powered trial is the open question.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.